Combination therapy to treat hepatitis B virus

A method for the treatment of hepatitis B virus in a human comprising administering in combination or alternation a synergistically effective amount of 2′-fluoro-5-methyl-β-L-arabinofuranolyluridine (L-FMAU), or a pharmaceutically acceptable salt, ester or prodrug thereof with an effective amount of a second anti-hepatitis B agent selected from the group consisting of penciclovir, 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA), or a pharmaceutically acceptable salt, ester or prodrug thereof and a compound of the formula

• 5
• wherein R is NH2, OH, Cl, or H, or a pharmaceutically acceptable salt, ester or prodrug thereof,.

A method for the treatment of hepatitis B virus in a human comprising administering in combination or alternation a synergistically effective amount of a compound of the formula

• 6
• wherein R is NH2, OH, Cl, or H, or a pharmaceutically acceptable salt, ester or prodrug thereof with an effective amount of a second anti-hepatitis B agent selected from the group consisting of PMEA, or a pharmaceutically acceptable salt, ester or prodrug thereof.

A pharmaceutical composition for the treatment of hepatitis B virus in a human comprising an effective amount of β-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β-FTC) or a pharmaceutically acceptable salt, ester, or prodrug thereof in a synergistic combination with an effective amount of a second anti-hepatitis B agent selected from the group consisting of penciclovir, famciclovir, and Bis-POM-PMEA.

A pharmaceutical composition for the treatment of hepatitis B virus in a human comprising an effective amount of 2′-fluoro-5-methyl-β-L-arabinofuranolyluridine (L-FMAU), or a pharmaceutically acceptable salt, ester or prodrug thereof in a synergistic combination with an effective amount of a second anti-hepatitis B agent selected from the group consisting of penciclovir, 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA), or a pharmaceutically acceptable salt, ester or prodrug thereof and a compound of the formula

• 7
• wherein R is NH2, OH, Cl, or H, or a pharmaceutically acceptable salt, ester or prodrug thereof,.

A pharmaceutical composition for the treatment of hepatitis B virus in a human comprising administering in combination or alternation a synergistically effective amount of a compound of the formula

• 8
• wherein R is NH2, OH, Cl, or H, or a pharmaceutically acceptable salt, ester or prodrug thereof with an effective amount of a second anti-hepatitis B agent selected from the group consisting of PMEA, or a pharmaceutically acceptable salt, ester or prodrug thereof.